Creating a Better Future for Families Affected by Rare Disease

February 7, 2022 -- With many of our team members impacted by rare disease themselves – our mission at Travere is personal. Read about what inspires our team’s determination to bring life-changing treatment, support and hope to people living with rare disease in this story in Fortune.
PharmaVoice Logo

For the CEO of Travere, running a rare disease company is personal

February 3, 2022 -- This week, PharmaVOICE featured a Q&A with our president and CEO Eric Dube on what it takes to succeed in rare disease. The key takeaway? The people within the company, the science, a patient-inspired culture, humility – and a true passion for making a difference. Read the article >
Life Sciences Voice Top Industry Leaders 2021 logo

In the News: Our president and CEO Eric Dube named Top Industry Leader by Life Sciences Voice

January 27, 2022 -- Eric Dube, president and CEO of Travere Therapeutics, was named a Top Industry Leader for 2021 by Life Sciences Voice. The magazine honored 50 distinguished individuals for this award. Read the article >

Travere Therapeutics Provides Corporate Update and 2022 Outlook

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2021 to be approximately $55 million.

Read the full press release >
Jula Inrig M.D.

Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement.

Read the full press release >
Newborn Screening

Landmark Study Calls for Modernization of Newborn Screening System in US

Rare families face too many challenges with our current newborn screening system in America. In partnership with patient advocates, Travere has been championing change at the federal and state level to catalyze advancements for patients.
RARE-X logo

Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).

Read the full press release >
RARE-X logo

Laura Clague and Eric Dube Named to San Diego Business Journal SD 500 Most Influential People in San Diego

November 29, 2021

Today, the San Diego Business Journal named our president and CEO Eric Dube, Ph.D., and our CFO Laura Clague in the top 500 executives in San Diego for 2021.
RARE-X logo

Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2021.

Read the full press release >
RARE-X logo

Travere Therapeutics Provides Corporate Update and 2022 Outlook

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2021 to be approximately $55 million. For the fiscal year 2021, the Company expects total revenue of $227 million, inclusive of approximately $211 million in net product sales and approximately $16 million in licensing and collaboration revenue. The Company also provided a general update on its development programs, including anticipated milestones for 2022.

Read the full press release >